Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07625293 · ClinicalTrials.gov registry record · Phase 2
DB-3Q for the Treatment of Medically Refractory Crohn's Disease
A Phase 2 study, sponsored by Direct Biologics.
- Not yet
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT07625293 is a Phase 2 study that has not yet begun recruiting, run by Direct Biologics. The registered enrollment target is 36 participants.
The verdict
NCT07625293, a Phase 2 study, has not yet begun recruiting, sponsored by Direct Biologics.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This research study is studying DB-3Q as a possible treatment for medically refractory Crohn's disease. The purpose of this study is to research and evaluate safety and effectiveness of the administration of bone marrow mesenchymal stem cell (bmMSC) derived extracellular vesicles product, DB-3Q, the study drug for Crohn's disease.
Interventions
- OTHER Placebo
- BIOLOGICAL DB-3Q
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07625293
The ClinicalTrials.gov registry entry for NCT07625293 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Direct Biologics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07625293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07625293 about?
NCT07625293 is a clinical study titled "DB-3Q for the Treatment of Medically Refractory Crohn's Disease". This research study is studying DB-3Q as a possible treatment for medically refractory Crohn's disease. The purpose of this study is to research and evaluate safety and effectiveness of the administration of bone marrow mesenchymal stem cell (bmMSC) derived extracellular vesicles product, DB-3Q, the...
What is the current status of trial NCT07625293?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2026-06. Estimated completion is 2027-12.
What interventions are being tested in trial NCT07625293?
The interventions under investigation include: Placebo (OTHER), DB-3Q (BIOLOGICAL).
Who is sponsoring clinical trial NCT07625293?
This trial is sponsored by Direct Biologics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.